Opinion

Video

Enfortumab Vedotin and the Role of ADCs in Bladder Cancer

Author(s):

Axel Merseburger, MD, PhD,M. Carmen Mir, MD, PhD

Bladder cancer specialists discuss enfortumab vedotin and the role of antibody-drug conjugates in the treatment landscape.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Newsletter

      Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

      Subscribe Now!
      Related Videos
      DNA helix | Image Credit: © Radomir Jovanovic - stock.adobe.com
      Betty Wang, MD, and Laura Bukavina, MD, MPH, MSc, discuss ctDNA's role in NMIBC treatment decisions
      Medical stethoscope and dollar bills | Image Credit: © Kuzmick - stock.adobe.com
      TMT for bladder cancer: Balancing cost and quality of life
      Anne Schuckman, MD, outlines current challenges in NMIBC care
      Anne Schuckman, MD, outlines current challenges in NMIBC care
      Daniel D. Joyce, MD, MS, answers a question during a Zoom video interview
      Investigators compare trimodal therapy vs cystectomy in MIBC
      Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
      Investigators assess ctDNA’s role in NMIBC
      Urology Times Mitomycin RX Review Square Thumb
      RX Review: Implementing mitomycin for LG-IR-NMIBC in clinical practice
      Urology Times Mitomycin RX Review Square Thumb
      RX Review: TURBT vs chemoablation for low-grade, intermediate-risk NMIBC
      Urology Times Mitomycin RX Review Square Thumb
      RX Review: A paradigm shift for low-grade, intermediate-risk NMIBC
      Urology Times Mitomycin RX Review Square Thumb
      RX Review: How mitomycin for intravesical solution works in treating LG-IR-NMIBC
      Urology Times Mitomycin RX Review Square Thumb
      RX Review: Redefining treatment for LG-IR-NMIBC
      Related Content
      Data supports combination intravesical chemotherapy for high-risk NMIBC
      July 10th 2025

      Data supports combination intravesical chemotherapy for high-risk NMIBC

      Hannah Clarke
      “This study adds to the growing body of evidence supporting combination intravesical chemotherapy as a feasible option even after prior treatment failure," says Ian M. McElree, MD.
      Dr. Schwen on focal therapies for prostate cancer
      January 11th 2024

      Dr. Schwen on focal therapies for prostate cancer

      Cleveland Clinic
      Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
      Human urinary system | Image Credit: © magicmine - stock.adobe.com
      July 8th 2025

      Enrollment complete for phase 3 UTOPIA trial in LG-IR-NMIBC

      Benjamin P. Saylor Hannah Clarke
      Eligible patients will receive UGN-103 75 mg intravesically once per week for 6 weeks.
      medical depiction of bladder cancer
      May 31st 2023

      Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

      Urology Times staff
      In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
      Regulatory recap: FDA approvals in urology from the first half of 2025
      July 4th 2025

      Regulatory recap: FDA approvals in urology from the first half of 2025

      Hannah Clarke
      Take a look through all the regulatory milestones in urology from the first half of the 2025.
      Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
      July 4th 2025

      Top 10 Urology Times videos from the first half of 2025

      Urology Times staff
      Catch up on exclusive videos you may have missed from the first half of the year.
      © 2025 MJH Life Sciences

      All rights reserved.